Surgery Partners (SGRY) Q3 Earnings and Revenues Lag Estimates

Surgery Partners (SGRY) reported Q3 earnings of $0.13 per share, falling short of the Zacks Consensus Estimate of $0.19 and down from $0.19 a year ago, representing a -31.58% surprise. Quarterly revenues of $821.5 million also narrowly missed expectations by 0.31%, though they increased from $770.4 million in the prior year. The surgical facilities operator's shares have underperformed the S&P 500 year-to-date, and the stock currently carries a Zacks Rank #3 (Hold), indicating an expectation of in-line market performance.

Analysis

Surgery Partners (SGRY) reported Q3 earnings of $0.13 per share, significantly missing the Zacks Consensus Estimate of $0.19, representing a -31.58% surprise and a decline from $0.19 a year ago. Quarterly revenues reached $821.5 million, narrowly missing the consensus estimate by 0.31%, despite growing from $770.4 million in the prior year.

This performance marks the third time in the last four quarters SGRY has missed EPS estimates, though it has topped revenue estimates twice in the same period. Year-to-date, SGRY shares have only gained 1.6%, substantially underperforming the S&P 500's 14.4% increase, indicating a sustained period of relative weakness.

The stock currently holds a Zacks Rank #3 (Hold), suggesting an expectation of in-line market performance in the near future, contingent on future earnings estimate revisions. Investors should closely monitor management's commentary during the earnings call for insights into the sustainability of future expectations, especially given the Medical Services industry's favorable position in the top 38% of Zacks industries.

Key Decisions for Investors

• Investors should scrutinize management's commentary on the earnings call for forward-looking guidance and any operational adjustments following the Q3 misses.
• Given the significant underperformance against the S&P 500 and the Zacks Rank #3 (Hold), a cautious approach may be warranted, focusing on whether upcoming Q4 EPS estimates of $0.46 and FY estimates of $0.92 are reiterated or revised.
• While the Medical Services industry shows strength, SGRY's specific execution challenges and mixed historical estimate performance suggest a need for careful evaluation of its individual trajectory within the sector.